Shares in Anika Therapeutics (NSDQ:ANIK) rose today after the orthopedics medicine company topped expectations on Wall Street with its second quarter results.
The Bedford, Mass.-based company posted profits of $11.4 million, or 78¢ per share, on sales of $33.5 million for the 3 months ended June 30, for bottom-line growth of 32% on sales growth of 26% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Anika tops EPS estimate by 32 cents in Q2 appeared first on MassDevice.
from MassDevice http://ift.tt/2uBodDk
Cap comentari:
Publica un comentari a l'entrada